Unique expression of HRF20 (CD59) in human nervous tissue

Microbiology and Immunology

Volumn 41, Issue 4, 1997, Pages 321-329

  Akatsu, Hiroyasu ^a,b   Yamada, Tatsuo ^c   Okada, Noriko ^a   Yamamoto, Takayuki ^b   Yamashina, Manabu ^b   Okada, Hidechika ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b Fukushimura Hospital   (Japan)

^c CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CNS; DAF(CD55); HRF20(CD59); MCP(CD46)

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; DECAY ACCELERATING FACTOR; GLYCOPROTEIN; MEMBRANE COFACTOR PROTEIN;

ARTICLE; CENTRAL NERVOUS SYSTEM; COMPLEMENT ACTIVATION; ENDOTHELIUM; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; NERVOUS TISSUE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PERIPHERAL NERVOUS SYSTEM; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHWANN CELL;

EID: 0030998808     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.1997.tb01208.x     Document Type: Article

References (42)

1. Asch, A.S., Kinoshita, T., Jaffe, E.A., and Nussenzweig, V. 1986. Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J. Exp. Med. 163: 221-226.
2. Compston, D.A.S., Morgan, B.P., Campbell, A.K., Wilkins, P., Cole, G., Thomas, N.D., and Jasani, B. 1989. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol. Appl. Neurobiol. 15: 307-316.
3. Cyong, J.C., Witkin, S.S., Rieger, B., Barbarese, E., Good, R.A., and Day, N.K. 1982. Antibody-independent complement activation by myelin via the classical complement pathway. J. Exp. Med. 155: 587-598.
4. Davies, A., Simmons, D.L., Hale, G., Harrison, R.A., Tighe, H., Lachmann, P.L., and Waldmann, H. 1989. CD59, an Ly-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med. 170: 637-654.
5. Fearon, D.T., and Austen, K.F. 1977. Activation of the alternative complement pathway due to resistance of zymosanbound amplification convertase to endogenous regulatory mechanisms. Proc. Natl. Acad. Sci. U.S.A. 74: 1683-1687.
6. Fujita, T., Inoue, T., Ogawa, K., Iida, K., and Tamura, N. 1987. The mechanism of action of decay-accelerating factor (DAF), DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J. Exp. Med. 166: 1221-1228.
7. Gordon, D.L., Sadlon, T.A., Wesselingh, S.L., Russell, S.M., Johnstone, R.W., and Purcell, D.F.J. 1992. Human astrocytes express membrane cofactor protein (CD46), a regulator of complement activation. J. Neuroimmunol. 36: 199-208.
8. Gordon, D.L., Sadlon, T., Hefford, C., and Adrian, D. 1993. Expression of CD59, a regulator of the membrane attack complex of complement, on human astrocytes. Mol. Brain Res. 18: 335-338.
9. Harada, R., Okada, N., Fujita, T., and Okada, H. 1990. Purification of 1F5 antigen that prevents complement attack on homologous cell membranes. J. Immunol. 144: 1823-1828.
10. Hideshima, T., Okada, N., and Okada, H. 1990. Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells. Immunology 69: 396-401.
11. Kinoshita, T., Medof, M.E., Silber, R., and Nussenzweig, V. 1985. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J. Exp. Med. 162: 75-92.
12. Kumar, S., Vinci, J.M., Pytel, B.A., and Baglioni, C. 1993. Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res. 53: 348-353.
13. Lachmann, P.J., and Halbwchs, L. 1975. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin. Exp. Immunol. 21: 109-114.
14. McGeer, P.L., Akiyama, H., Itagaki, S., and McGeer, E.G. 1989. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107: 341-346.
15. McGeer, P.L., Walker, D.G., Akiyama, H., Kawamata, T., Guan, A.L., Parker, C.J., Okada, N., and McGeer, E.G. 1991. Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res. 544: 315-319.
16. McNearney, T., Ballard, L., Seya, T., and Atkinson, J.P. 1989. Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. J. Clin. Invest. 84: 538-545.
17. Meri, S., Waldmann, H., and Lachmann, P.J. 1991. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab. Invest. 65: 532-537.
18. Motoyama, N., Okada, N., Yamashina, M., and Okada, H. 1992. Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene. Eur. J. Immunol. 22: 2669-2673.
19. Nicholson-Weller, A., Burge, J., Fearon, D.T., Weller, P.F., and Ausen, K.F. 1982. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertase of the complement system. J. Immunol. 129: 184-189.
20. Nicholson-Weller, A., March, J.P., Rosen, C.E., Spicer, D.B., and Austen, K.F. 1985. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood 65: 1237-1244.
21. Nose, M., Katoh, M., Okada, N., Kyogoku, M., and Okada, H. 1990. Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology 70: 145-149.
22. Okada, H., Nagami, Y., Takahashi, K., Okada, N., Hideshima, T., Takizawa, H., and Kondo, J. 1989. 20 KDa homologous restriction factor of complement resembles T cell activating protein. Biochem. Biophys. Res. Commun. 162: 1553-1559.
23. Okada, N., Harada, R., Fujita, T., and Okada, H. 1989. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int. Immunol. 1: 205-208.
24. Okada, N., Harada, R., Fujita, T., and Okada, H. 1989. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. J. Immunol. 143: 2262-2266.
25. Pangburn, M.K., and Müller-Eberhard, H.J. 1980. Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J. Exp. Med. 152: 1102-1114.
26. Pangburn, M.K., Schreiber, R.D., and Müller-Eberhard, H.J. Formation of the initial C3 convertase of the alternative complement pathway. J. Exp. Med. 154: 856-867.
27. Schönermark, S., Rauterberg, E.W., Shin, M.L., Löke, S., Roelcke, D., and Hänsch, G.M. 1986. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J. Immunol. 136: 1772-1776.
28. Seya, T., Turner, J.R., and Atkinson, J.P. 1986. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4d. J. Exp. Med. 163: 837-855.
29. Seya, T., Ballard, L.L., Bora, N.S., Kumar, V., Cui, W., and Atkinson, J.P. 1988. Distribution of membrane cofactor protein of complement on human peripheral blood cells. An altered form is found on granulocytes. Eur. J. Immunol. 18: 1289-1294.
30. Seya, T., Hara, T., Matsumoto, M., and Akedo, H. 1990. Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation. J. Immunol. 145: 238-245.
31. Takahashi, M., Lajos, B., Sakurada, C., Yamamoto, T., Okada, N., and Okada, H. 1995. Expression of C5a receptor in the central nervous system, proceeding of complement symposium. 32: 65-68 (in Japanese).
32. Takaizawa, H., Okada, N., and Okada, H. 1994. Complement inhibitor of rat cell membrane resembling mouse Crry/p65. J. Immunol. 152: 3032-3038.
33. Vanguri, P., Koski, C.L., Silverman, B., and Shin, A.M. 1982. Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies. Proc. Natl. Acad. Sci. U.S.A. 79: 3290-3294.
34. Vedeler, C., Ulvestad, E., Bjorge, L., Conti, G., Williams, K., Mork, S., and Matre, R. 1994. The expression of CD59 in normal human nervous tissue. Immunology 82: 542-547.
35. Walker, D.G., and McGeer, P.L. 1993. Complement gene expression in neuroblastoma and astrocytoma cell lines of human origin. Neurosci. Lett. 157: 99-102.
36. Walker, D.G., Kim, S.U., and McGeer, P.L. 1995. Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. J. Neurosci. Res. 40: 478-493.
37. Walker, D.G., Yasuhara, O., Patston, P.A., McGeer, E.G., and McGeer, P.L. 1995. Complement Cl inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res. 675: 75-82.
38. Yamada, T., Akiyama, H., and McGeer, P.L. 1990. Complement-activated oligodendroglia: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d. Neurosci. Lett. 112: 161-166.
39. Yamashina, M., Ueda, E., Kinoshita, T., Takami, T., Ojima, A., Ono, H., Tanaka, H., Kondo, N., Orii, T., Okada, N., Okada, H., Inoue, K., and Kitani, T. 1990. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. New Engl. J. Med. 323: 1184-1189.
40. Yang, C., Jones, J.L., and Barnum, S.R. 1993. Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes. J. Neuroimmunol. 47: 123-132.
41. Yasuhara, O., Aimi, Y., McGeer, E.G., and McGeer, P.L. 1994. Expression of the complement membrane attack complex and its inhibitor in Pick disease brain. Brain Res. 652: 346-349.
42. Zajicek, J., Wing, M., Skepper, J., and Compston, A. 1995. Human oligodendrocytes are not sensitive to complement. Lav. Invest. 73: 128-138.